Latest SEC filings for Abbott Laboratories (ABT) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). All data sourced directly from SEC EDGAR — last updated 2026-07-28.
ABBOTT LABORATORIES filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.
ABBOTT LABORATORIES filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
Stratton John G (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Roman Michael F (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Gonzalez Patricia Paola (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Conroy Kevin T (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Ahuja Nita (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Morrone Louis H. (EXECUTIVE VICE PRESIDENT) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Cushman Elizabeth C. (EVP, GC AND SECRETARY) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Stratton John G, listed as Director at ABBOTT LABORATORIES, reported an open-market purchase of 2,000 ABT shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.
Robert J. Alpern filed a Form 144 with the SEC indicating intent to sell ABT (ABBOTT LABORATORIES) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Moreland Mary K (EXECUTIVE VICE PRESIDENT) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
ABBOTT LABORATORIES filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.
Conroy Kevin T (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Stratton John G (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
STARKS DANIEL J, listed as Director at ABBOTT LABORATORIES, reported an open-market purchase of 10,000 ABT shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.
Roman Michael F (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
O'Grady Michael (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
McKinstry Nancy (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
McDew Darren W (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Executives, directors, and large shareholders must report any purchase or sale of ABT shares within two business days. Consistent buying by multiple insiders is often read as a confidence signal; large sales may reflect diversification or liquidity needs rather than negative conviction.
Filed when a company affiliate intends to sell restricted or control shares. A Form 144 is a notice of intent, not confirmation — the actual sale is later confirmed via Form 4. It gives investors advance visibility into planned insider selling activity.
The 8-K is an event-driven filing that Abbott Laboratories must submit within four business days of a significant development — including earnings results, mergers, executive changes, credit facility updates, or regulatory actions. Each 8-K item code maps to a specific event type.
The 10-Q (quarterly) and 10-K (annual) are comprehensive reports covering Abbott Laboratories's financial results, risk factors, management discussion, and business operations. The 10-K includes audited financials and is the most complete public disclosure the company makes each year.
View valuation, growth metrics, AI Strong Buy score, demand zones, peer comparison, and more — all on the ABT stock analysis page.